Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Decitabine + GM-CSF + PD-1 inhibitor for newly treated elderly AML
ChiCTR2200056635Phase 4Recruiting
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Mar 2022
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of decitabine and sargramostim in acute myeloid leukemia (AML), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Total response rate (ORR), Progression-free survival (PFS) and 2 more. Started Mar 2022; status: recruiting.
02
Drugs
decitabinesargramostim
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on ChiCTR2200056635.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056635.